Desjardins Global Asset Management Inc. Neurocrine Biosciences Inc Transaction History
Desjardins Global Asset Management Inc.
- $922 Million
- Q4 2023
A detailed history of Desjardins Global Asset Management Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Desjardins Global Asset Management Inc. holds 433 shares of NBIX stock, worth $49,340. This represents 0.01% of its overall portfolio holdings.
Number of Shares
433
Previous 427
1.41%
Holding current value
$49,340
Previous $48,000
18.75%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
641Shares Held
95.2MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.62 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.15 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$525 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$281 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$269 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...